WS #16472
The US government has announced a policy shift allowing the compounding of six specific peptides, a move that is expected to lower costs and increase access to these treatments. This regulatory change is directly benefiting Hims & Hers, whose stock rose on the news. The development signals a potential expansion in the telehealth and specialty pharmacy markets, offering a niche growth opportunity within the healthcare sector.
US Peptide Policy Shift
The US government has announced a policy shift allowing the compounding of six specific peptides, a move that is expected to lower costs and increase access to these treatments. This regulatory change is directly benefiting Hims & Hers, whose stock rose on the news. The development signals a potential expansion in the telehealth and specialty pharmacy markets, offering a niche growth opportunity within the healthcare sector.